Received Jun 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2GZ34 | — |
Administration after Below temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 48-year-old female patient who received HBV (Engerix B) suspension for injection in pre-filled syringe (batch number 2GZ34) for prophylaxis. On 18-MAY-2026, the patient received Engerix B. On 18-MAY-2026, an unknown time after receiving Engerix B, the patient experienced incorrect storage of drug (Verbatim: Administration after Below temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Linked case(s) involving the same patient: US2026074478 Additional Information: GSK Receipt Date: 04-JUN-2026 The reporter mentioned that on 11-MAY-2026 Boostrix, Engerix-B, Havrix, Menveo (1 vial) and Shingrix (PFS) vaccines were exposed with a minimum temperature of 30-degree F for 2 hours. 19 patients had received the vaccines after the excursion and asked if the patients needed to be revaccinated. This was report 6/19. The patient received Engerix-B on 18-MAY-2026.; Sender's Comments: US-GSK-US2026074486: US-GSK-US2026074481:SAME REPORTER US-GSK-US2026074706:SAME REPORTER US-GSK-US2026074484:SAME REPORTER US-GSK-US2026074480:SAME REPORTER US-GSK-US2026074485: US-GSK-US2026074479: US-GSK-US2026074483:SAME REPORTER